CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The researchers enrolled DLBCL patients with relapsed or refractory disease who had already received at least two lines of treatment in the phase 2 portion of a phase 1-2 investigation. They concluded that treatment with glofitamab was successful for DLBCL, with more than half of the patients experiencing a grade 3 or 4 adverse event.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
